{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:25:11Z","timestamp":1789086311861,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Onychomycosis is a fungal infection of the toenails or fingernails that can involve any component of the nail unit, including the matrix, bed, and plate. It is a common disorder that may be a reservoir for infection resulting in significant medical problems. Moreover, onychomycosis can have a substantial influence on one\u2019s quality of life. An understanding of the disorder and updated management is important for all health care professionals. Aside from reducing quality of life, sequelae of the disease may include pain and disfigurement, possibly leading to more serious physical and occupational limitations. Dermatologists, Podiatrists, and other clinicians who treat onychomycosis are now entering a new era when considering treatment options\u2014topical modalities are proving more effective than those of the past. The once sought after concept of viable, effective, well-tolerated, and still  easy-to-use monotherapy alternatives to oral therapy treatments for onychomycosis is now within reach given recent study data. In addition, these therapies may also find a role in combination and maintenance therapy; in order to treat the entire disease the practitioner needs to optimize these topical agents as sustained therapy after initial clearance to reduce recurrence or re-infection given the nature of the disease.<\/jats:p>","DOI":"10.3390\/jof1020173","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T10:51:50Z","timestamp":1439981510000},"page":"173-184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Dermatologist\u2019s Approach to Onychomycosis"],"prefix":"10.3390","volume":"1","author":[{"given":"Jenna","family":"Queller","sequence":"first","affiliation":[{"name":"Dermatology Chief Resident at Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA 92123, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"ref_1","unstructured":"Scher, R.K., and Daniel, C.R. (2005). Nails: Therapy, Diagnosis, Surgery, Elsevier Saunders. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3810\/pgm.1998.02.359","article-title":"Common dermatophyte infections. A simple diagnostic test and current management","volume":"103","author":"Crissey","year":"1998","journal-title":"Postgrad. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0190-9622(96)90675-1","article-title":"A U.S. epidemiologic survey of superficial fungal diseases","volume":"35","author":"Kemna","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis. Treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: Pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","first-page":"513","article-title":"Diagnosing and treating onychomycosis","volume":"42","author":"Zaias","year":"1996","journal-title":"J. Fam. Pract."},{"key":"ref_7","first-page":"s96","article-title":"Onychomycosis: An Overview","volume":"12","author":"Elewski","year":"2013","journal-title":"J Drugs Dermatol."},{"key":"ref_8","unstructured":"Elewski, B. (1992). Cutaneous Fungal Infections, Igaku-Shoin Inc."},{"key":"ref_9","first-page":"699","article-title":"The prevalence of onychomycosis in Finland","volume":"133","author":"Stubb","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(97)80215-0","article-title":"Onychomycosis in children: Prevalence and treatment strategies","volume":"36","author":"Gupta","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","first-page":"1","article-title":"The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: A prospective controlled trial","volume":"32","author":"Ergin","year":"2007","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2133.1997.tb03673.x","article-title":"A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicentre study","volume":"136","author":"Gupta","year":"1997","journal-title":"Br J Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archdermatol.2011.267","article-title":"A new classification system for grading the severity of onychomycosis; Onychomycosis Severity Index","volume":"147","author":"Carney","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_15","first-page":"305","article-title":"Topical treatment of onychomycosis with efinaconazole solution 10%","volume":"91","author":"Rich","year":"2013","journal-title":"Cutis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: Development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"41","author":"Drake","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(96)90061-4","article-title":"Onychomycosis: A significant medical disorder","volume":"35","author":"Scher","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0190-9622(98)70486-4","article-title":"Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg\/day vs. itraconazole 200 mg\/day","volume":"38","author":"Lesaffre","year":"1998","journal-title":"J Am Acad Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0190-9622(98)70490-6","article-title":"Once-weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the toenail","volume":"38","author":"Scher","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000277762","article-title":"Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents","volume":"220","author":"Ruffleux","year":"2010","journal-title":"Dermatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","first-page":"663","article-title":"Treating onychomycosis","volume":"63","author":"Rogers","year":"2001","journal-title":"Am. Fam. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7547\/0970195","article-title":"Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: A multicenter, open-label study","volume":"97","author":"Brenner","year":"2007","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_25","first-page":"1","article-title":"Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis","volume":"18","author":"Gupta","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_26","first-page":"10","article-title":"Efinaconazole Topical Solution, 10%: Formulation Development Program of a New Topical Treatment of Toenail Onychomycosis","volume":"10","author":"Bhatt","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","article-title":"Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis","volume":"57","author":"Tatsumi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","article-title":"Mechanism of antifungal action of efinaconazole, a novel triazole agent","volume":"57","author":"Tatsumi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","first-page":"24","article-title":"Efinaconazole Topical Solution, 10%, for the treatment of Mild and Moderate Toenail Onychomycosis","volume":"8","author":"Rodriguez","year":"2015","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_30","first-page":"1394","article-title":"Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space","volume":"13","author":"Elewski","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_31","first-page":"34","article-title":"Penetration of (14C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish","volume":"7","author":"Zeichner","year":"2014","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized double blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","article-title":"Recent progress in the topical therapy of onychomycosis","volume":"16","author":"Alley","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_34","unstructured":"(2014). Kerydin (Package Insert), Anacor Pharmaceuticals, Inc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","article-title":"Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies","volume":"73","author":"Elewski","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/jps.20901","article-title":"In Vitro Penetration of a Novel Oxaborole Antifungal (AN2690) into the Human Nail Plate","volume":"96","author":"Hui","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaad.2004.10.876","article-title":"Long-pulsed neodymium: Yttrium-aluminum-garnet laser treatment for port-wine stains","volume":"52","author":"Yang","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/14764172.2011.552616","article-title":"Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd: YAG 1064-nm laser","volume":"13","author":"Hochman","year":"2011","journal-title":"J. Cosmet. Laser Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/14764172.2014.910082","article-title":"Treatment of onychomycosis with a 1064-nm long-pulsed Nd: YAG laser","volume":"16","author":"Moon","year":"2014","journal-title":"J. Cosmet. Laser Ther."},{"key":"ref_41","first-page":"496","article-title":"Treating onychomycoses of the toenail: Clinical efficacy of the sub-millisecond 1064 nm Nd: YAG laser using a 5 mm spot diameter","volume":"11","author":"Kimura","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7547\/87507315-74-10-509","article-title":"Preliminary report on use of carbon dioxide laser in podiatry","volume":"74","author":"Apfelberg","year":"1984","journal-title":"J. Am. Podiatry Assoc."},{"key":"ref_43","first-page":"123","article-title":"Noninvasive CO laser fenestration improves treatment of onychomycosis","volume":"10","author":"Borovoy","year":"1992","journal-title":"Clin. Laser Mon."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S1466252311000016","article-title":"Ultraviolet irradiation and the mechanisms underlying its inactivation of infections agents","volume":"12","author":"Cutler","year":"2011","journal-title":"Anim. Health Res. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1365-2133.2008.08549.x","article-title":"Ultraviolet C inactivation of dermatophytes: Implications for treatment of onychomycosis","volume":"158","author":"Dai","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10103-013-1287-4","article-title":"An investigation into the inhibitory effect of UV radiation on T. rubrum","volume":"29","author":"Chronin","year":"2014","journal-title":"Lasers Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2340\/00015555-0811","article-title":"Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial","volume":"90","author":"Sotiriou","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2008.06.015","article-title":"Photodynamic therapy of onychomycosis caused by Trichophyton rubrum","volume":"59","author":"Piraccini","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1751-1097.2009.00615.x","article-title":"Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures","volume":"85","author":"Bornstein","year":"2009","journal-title":"Photochem. Photobiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7547\/1000166","article-title":"Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure","volume":"100","author":"Landsman","year":"2010","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7547\/1020169","article-title":"Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: Some follow-up observations at 270 days","volume":"102","author":"Landsman","year":"2012","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_52","first-page":"694","article-title":"Managing Assessments and Expectations: Patient Responses Following Therapy with Efinaconazole Topical Solution, 10%","volume":"14","author":"Bhatia","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_53","first-page":"58","article-title":"Efinaconazole topical solution, 10%: The benefit of treating onychomycosis early","volume":"14","author":"Rich","year":"2015","journal-title":"J. Drugs Dermatol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/1\/2\/173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:47:02Z","timestamp":1760215622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/1\/2\/173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["jof1020173"],"URL":"https:\/\/doi.org\/10.3390\/jof1020173","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]}}}